Positron Pharmaceuticals

Positron Pharmaceuticals is the radiopharmaceutical subsidiary of Positron Corporation, a nuclear medicine healthcare company. Formed in 2008 following the acquisition of Dose Shield Corporation, the company focuses on the development, manufacturing, and distribution of radiopharmaceuticals and medical isotopes, particularly for nuclear cardiology. Its product portfolio includes Indium Oxine (Indium-111 oxyquinoline) for infection imaging and Rubidium-82 generators used in PET myocardial perfusion imaging. The company aims to provide a vertically integrated solution for nuclear medicine, combining imaging systems with the necessary radiopharmaceutical tracers and automated dose delivery equipment.